M
Michael A. Choti
Researcher at University of Texas Southwestern Medical Center
Publications - 405
Citations - 41328
Michael A. Choti is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Hepatectomy & Cancer. The author has an hindex of 99, co-authored 398 publications receiving 37028 citations. Previous affiliations of Michael A. Choti include University of Milan & Intuitive Surgical.
Papers
More filters
Journal ArticleDOI
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda,Chetan Bettegowda,Mark Sausen,Rebecca J. Leary,Isaac Kinde,Yuxuan Wang,Nishant Agrawal,Nishant Agrawal,Bjarne Bartlett,Bjarne Bartlett,Hao Wang,Brandon Luber,Rhoda M. Alani,Emmanuel S. Antonarakis,Nilofer S. Azad,Alberto Bardelli,Henry Brem,John L. Cameron,Clarence Lee,Leslie A. Fecher,Leslie A. Fecher,Gary L. Gallia,Peter Gibbs,Dung T. Le,Dung T. Le,Robert L. Giuntoli,Michael Goggins,Michael D. Hogarty,Matthias Holdhoff,Seung-Mo Hong,Seung-Mo Hong,Yuchen Jiao,Hartmut Juhl,Jenny J. Kim,Giulia Siravegna,Daniel A. Laheru,Calogero Lauricella,Michael Lim,Evan J. Lipson,Suely Kazue Nagahashi Marie,George J. Netto,Kelly S. Oliner,Alessandro Olivi,Louise Olsson,Gregory J. Riggins,Andrea Sartore-Bianchi,Kerstin Schmidt,le-Ming Shih,Sueli Mieko Oba-Shinjo,Salvatore Siena,Dan Theodorescu,Jeanne Tie,Timothy T. Harkins,Silvio Veronese,Tian Li Wang,Jon D. Weingart,Christopher L. Wolfgang,Laura D. Wood,Dongmei Xing,Ralph H. Hruban,Jian Wu,Peter J. Allen,C. Max Schmidt,Michael A. Choti,Victor E. Velculescu,Kenneth W. Kinzler,Bert Vogelstein,Nickolas Papadopoulos,Luis A. Diaz,Luis A. Diaz +69 more
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Journal ArticleDOI
Daxx/atrx, men1, and mtor pathway genes are frequently altered in pancreatic neuroendocrine tumors
Yuchen Jiao,Chanjuan Shi,Barish H. Edil,Roeland F. de Wilde,David S. Klimstra,Anirban Maitra,Richard D. Schulick,Laura H. Tang,Christopher L. Wolfgang,Michael A. Choti,Victor E. Velculescu,Luis A. Diaz,Bert Vogelstein,Kenneth W. Kinzler,Ralph H. Hruban,Nickolas Papadopoulos +15 more
TL;DR: Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis and a finding that could potentially be used to stratify patients for treatment with mTOR inhibitors was found.
Journal ArticleDOI
Trends in long-term survival following liver resection for hepatic colorectal metastases.
Michael A. Choti,James V. Sitzmann,Marcelo F. Tiburi,Wuthi Sumetchotimetha,Ram Rangsin,Richard D. Schulick,Keith D. Lillemoe,Charles J. Yeo,John L. Cameron +8 more
TL;DR: Long-term survival following liver resection for colorectal metastases has improved significantly in recent years at this institution, and contributing factors may include the use of newer preoperative and intraoperative imaging, increased use of chemotherapy, and salvage surgical therapy.
Journal ArticleDOI
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.
Jordan M. Winter,John L. Cameron,Kurtis A. Campbell,Meghan A. Arnold,David C. Chang,Jo Ann Coleman,Mary Hodgin,Patricia K. Sauter,Ralph H. Hruban,Taylor S. Riall,Richard D. Schulick,Michael A. Choti,Keith D. Lillemoe,Charles J. Yeo +13 more
TL;DR: Patients who have cancers with favorable pathological features have a statistically significant improved long-term survival, and pathological factors having a significant impact on survival included tumor diameter, resection margin status, lymph node status, and histologic grade.
Journal ArticleDOI
Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution
Michelle L. DeOliveira,Steven C. Cunningham,Steven C. Cunningham,John L. Cameron,Farin Kamangar,Jordan M. Winter,Keith D. Lillemoe,Keith D. Lillemoe,Michael A. Choti,Charles J. Yeo,Charles J. Yeo,Richard D. Schulick +11 more
TL;DR: R0 resection remains the best chance for long-term survival, and lymph node status is the most important prognostic factor following R1 resection, according to a large series of patients with bile duct cancer.